Go Pro
→ Is an AI “Kill Switch” coming? (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$213.68
-0.5%		$235.91
$107.81
▼
$260.19
$11.24B0.65754,628 shs705,304 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$110.51
-1.5%		$92.50
$28.66
▼
$122.21
$12.13B0.451.33 million shs740,195 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.52
+1.8%		$24.56
$17.11
▼
$27.98
$11.06B1.678.32 million shs5.57 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.72
+0.4%		$13.51
$5.69
▼
$13.72
$3.59B1.552.66 million shs2.08 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-0.46%+1.69%-9.17%-6.17%+95.34%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-1.49%+2.37%+22.15%+96.04%+51.80%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+1.91%-7.04%-11.89%+13.44%+26.32%
Organon & Co. stock logo
OGN
Organon & Co.
+0.40%+1.18%+1.59%+2.39%+46.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$213.68
-0.5%		$235.91
$107.81
▼
$260.19
$11.24B0.65754,628 shs705,304 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$110.51
-1.5%		$92.50
$28.66
▼
$122.21
$12.13B0.451.33 million shs740,195 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.52
+1.8%		$24.56
$17.11
▼
$27.98
$11.06B1.678.32 million shs5.57 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.72
+0.4%		$13.51
$5.69
▼
$13.72
$3.59B1.552.66 million shs2.08 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-0.46%+1.69%-9.17%-6.17%+95.34%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-1.49%+2.37%+22.15%+96.04%+51.80%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+1.91%-7.04%-11.89%+13.44%+26.32%
Organon & Co. stock logo
OGN
Organon & Co.
+0.40%+1.18%+1.59%+2.39%+46.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.82
Moderate Buy$267.6025.23% Upside
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
2.63
Moderate Buy$119.177.83% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$29.0929.17% Upside
Organon & Co. stock logo
OGN
Organon & Co.
1.71
Reduce$11.40-16.88% Downside

Current Analyst Ratings Breakdown

Latest OGN, CORT, ELAN, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$306.00 ➝ $316.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$304.00 ➝ $297.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$242.00 ➝ $251.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$260.00 ➝ $275.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy ➝ Market Perform
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$255.00 ➝ $256.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$267.00 ➝ $268.00
8/6/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$31.00 ➝ $33.00
8/6/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$29.00 ➝ $30.00
8/3/2026
Organon & Co. stock logo
OGN
Organon & Co.
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
7/31/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M17.53N/AN/A$1.75 per share122.10
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$830.81M14.38$0.89 per share124.27$6.53 per share16.92
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.39$2.36 per share9.54$13.19 per share1.71
Organon & Co. stock logo
OGN
Organon & Co.
$6.22B0.58$5.81 per share2.36$3.83 per share3.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.75N/A50.52N/A-24.68%-275.76%-28.82%N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$99.65M$0.42263.1347.03N/A6.52%8.26%6.45%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.41N/A17.871.33-3.96%8.13%3.99%N/A
Organon & Co. stock logo
OGN
Organon & Co.
$187M$0.7717.813.991.263.41%88.97%6.03%N/A

Latest OGN, CORT, ELAN, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.8921-$0.99-$0.0980-$0.99$221.11 million$218.38 million
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.2692$0.34+$0.0708$0.11$1.31 billion$1.37 billion
7/29/2026Q2 2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.0243$0.36+$0.3357$0.36$221.15 million$256.15 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.58%N/A10.39%N/A

Latest OGN, CORT, ELAN, and AXSM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/31/2026
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.59%8/14/20268/14/20269/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.32
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
2.86
2.77
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.58
2.05
1.10
Organon & Co. stock logo
OGN
Organon & Co.
8.43
1.95
1.44

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.70%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Organon & Co. stock logo
OGN
Organon & Co.
1.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38052.38 million41.59 millionOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300108.10 million85.72 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.62 million493.93 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000262.61 million258.36 millionNot Optionable

Recent News About These Companies

Quantinno Capital Management LP Sells 98,466 Shares of Organon & Co. $OGN
August 13 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-sells-98466-shares-of-organon-co-ogn-2026-08-13/
Sei Investments Co. Has $1.14 Million Holdings in Organon & Co. $OGN
August 13 at 4:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sei-investments-co-has-114-million-holdings-in-organon-co-ogn-2026-08-13/
Organon & Co. (NYSE:OGN) Reaches New 1-Year High - Should You Buy?
August 13 at 4:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/organon-co-nyseogn-reaches-new-1-year-high-should-you-buy-2026-08-13/
Organon & Co. (OGN)
August 13 at 2:46 AM  |  sg.finance.yahoo.comhttps://sg.finance.yahoo.com/quote/OGN/news/
Organon & Co. $OGN Shares Purchased by California State Teachers Retirement System
August 12 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-organon-co-ogn-shares-purchased-by-california-state-teachers-retirement-system-2026-08-12/
Rep. Kevin Hern Sells Shares of Organon & Co. (NYSE:OGN)
August 12 at 2:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rep-kevin-hern-sells-shares-of-organon-co-nyseogn-2026-08-12/
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
August 11 at 7:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260811268677/en/organon-opens-rems-program-for-miudella%c2%ae-ahead-of-anticipated-commercial-availability/
Organon & Co. (NYSE:OGN) Reaches New 52-Week High - Should You Buy?
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/organon-co-nyseogn-reaches-new-52-week-high-should-you-buy-2026-08-07/
Organon & Co. $OGN Shares Sold by Dimensional Fund Advisors LP
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-organon-co-ogn-shares-sold-by-dimensional-fund-advisors-lp-2026-08-07/
Analysts Set Organon & Co. (NYSE:OGN) PT at $11.40
August 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30939926
Organon & Co. (NYSE:OGN) to Issue $0.02 Quarterly Dividend
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/organon-co-nyseogn-to-issue-002-quarterly-dividend-2026-07-31/
Organon & Co. (NYSE:OGN) Issues Earnings Results, Misses Expectations By $0.02 EPS
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/organon-co-nyseogn-issues-earnings-results-misses-expectations-by-002-eps-2026-07-31/
Organon: Q2 Earnings Snapshot
July 31, 2026  |  stamfordadvocate.comS
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
July 31, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2965859/compared-to-estimates-organon-ogn-q2-earnings-a-look-at-key-metrics?cid=cs-stocknewsapi-ft-fundamental_analysis|nfm-2965859
Organon (OGN) Lags Q2 Earnings Estimates
July 31, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2965694/organon-ogn-lags-q2-earnings-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2965694
Organon Announces Quarterly Dividend
July 31, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260731734106/en/Organon-Announces-Quarterly-Dividend/
Organon Reports Q2 Results Amid Pending Sun Pharma Merger
July 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/organon-reports-q2-results-amid-pending-sun-pharma-merger?utm_source=marketbeat.com&utm_medium=referral
Orographic Financial Advisors LLC Acquires New Holdings in Organon & Co. $OGN
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-orographic-financial-advisors-llc-acquires-new-holdings-in-organon-co-ogn-2026-07-31/
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/organon-co-nyseogn-receives-average-rating-of-reduce-from-brokerages-2026-07-30/
First Trust Advisors LP Has $19.33 Million Position in Organon & Co. $OGN
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-first-trust-advisors-lp-has-1933-million-position-in-organon-co-ogn-2026-07-30/
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
July 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2961788/organon-co-ogn-is-attracting-investor-attention-here-is-what-you-should-know?cid=cs-stocknewsapi-ft-tale_of_the_tape|most_searched_stocks_v1-2961788

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$213.68 -0.98 (-0.46%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$213.69 +0.01 (+0.00%)
As of 08/13/2026 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$110.51 -1.67 (-1.49%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$110.45 -0.06 (-0.05%)
As of 08/13/2026 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$22.52 +0.39 (+1.77%)
Closing price 08/13/2026 03:59 PM Eastern
Extended Trading
$22.55 +0.03 (+0.12%)
As of 08/13/2026 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$13.72 +0.06 (+0.40%)
Closing price 08/13/2026 03:59 PM Eastern
Extended Trading
$13.68 -0.04 (-0.26%)
As of 08/13/2026 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas